Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission - Inspira Technologies Oxy (NASDAQ:IINN)

Core Insights - Inspira Technologies has completed the clinical study for its non-invasive blood sensor, HYLA, and is preparing for regulatory submission and commercialization [1][2][4] - The HYLA sensor demonstrates an accuracy rate between 95% to 99% across various measured parameters, indicating its potential as a disruptive solution for real-time blood monitoring [2][4] - The company is integrating advanced Machine Learning algorithms to enhance the capabilities of the HYLA sensor, aiming to monitor critical physiological parameters not currently available through existing non-invasive systems [3][4] Company Overview - Inspira Technologies is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA ART100 system [5] - The company is developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake, further expanding its product offerings [5] - Inspira Technologies is positioned as an attractive player in the life-support and MedTech landscape, with a growing intellectual property portfolio and strategic operational streamlining [5]